In patients with advanced NSCLC, anti-PD-1 monotherapy can achieve a median OS of 11.9 months, which was significantly superior to that with a SOC at 9.5 months (hazard ratio [HR]: 0.75; 95% confidence interval [CI]: 0.61–0.93). Here, PDCD1 is linked to non-small cell lung carcinoma.